Genesis Care North Shore
Welcome,         Profile    Billing    Logout  
 4 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Krieger, Laurence
BCG+MMC, NCT02948543: Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer

Active, not recruiting
3
501
Europe, RoW
Bacillus of Calmette-Guerin (BCG), OncoTICE, ImmuCYST, TheraCys, Mitomycin (MM)
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cancer Australia
Bladder Cancer
12/24
12/24
DASL-HiCaP, NCT04136353: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

Active, not recruiting
3
1100
Europe, Canada, US, RoW
Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Bayer, Cancer Trials Ireland, Canadian Cancer Trials Group, Memorial Sloan Kettering Cancer Center, Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/28
07/28
KEYPAD, NCT03280667: Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma

Active, not recruiting
2
59
RoW
Pembrolizumab plus denosumab, Keytruda and Xgeva
Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Merck Sharp & Dohme LLC, Amgen
Renal Cell Carcinoma, Clear Cell, Metastatic Kidney Cancer
06/23
06/23
NCT05146973: External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET)

Active, not recruiting
2
5
RoW
177Lu-DOTA-TLX591
Telix Pharmaceuticals (Innovations) Pty Limited
Prostate Cancer
07/23
08/24
ENZA-p, NCT04419402: Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer

Active, not recruiting
2
162
RoW
Lu-PSMA, 177Lutetium -PSMA 617 also referred to as 177Lu-PSMA, Enzalutamide, Xtandi
Australian and New Zealand Urogenital and Prostate Cancer Trials Group, National Health and Medical Research Council, Clinical Trials Centre, Prostate Cancer Research Alliance, Endocyte, Astellas Pharma Inc
Metastatic Castration-Resistant Prostate Cancer
07/24
01/25
WOMBAT, NCT06594926: Working Out M0 Bipolar Androgen Therapy

Recruiting
2
69
RoW
Testosterone Enanthate, Primoteston Depot
Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Bayer, The George Institute, HMRI
Prostate Cancer
12/26
12/28
KEYNOTE-D78, NCT04879329: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Recruiting
2
332
Europe, Canada, Japan, US, RoW
disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Urothelial Carcinoma
11/26
05/28
DECREASE, NCT04319783: Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA

Recruiting
2
87
RoW
Darolutamide, NUBEQA, Bayer HealthCare Pharmaceuticals Inc., Radiotherapy
Trans Tasman Radiation Oncology Group, Bayer, Peter MacCallum Cancer Centre, Australia
Advanced Prostate Carcinoma, Cancer of Prostate, PSA, Castrate Resistant Prostate Cancer
06/26
06/26
ANZadapt, NCT05393791: Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC

Recruiting
2
168
Europe, RoW
Patient-specific adaptive therapy, Abiraterone acetate, Zytiga, Enzalutamide, Xtandi
Leiden University Medical Center, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Anticancer Fund, Belgium
Prostatic Neoplasms, Castration-Resistant
11/27
11/27
NCT06351904: A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

Recruiting
1
15
RoW
RAG-01
Ractigen Therapeutics.
Non-Muscle-Invasive Bladder Cancer (NMIBC)
06/25
08/25
KEYNOTE-F35, NCT05614739: A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3

Recruiting
1
180
Europe, Canada, Japan, US, RoW
LOXO-435, LY3866288, Pembrolizumab, KEYTRUDA®
Eli Lilly and Company, Merck Sharp & Dohme LLC
Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
06/25
06/25

Download Options